Mouse anti Guinea Pig TNF monoclonal antibody, clone 670917 [Biotin]

Background: The aetiology of postdialysis fatigue (PDF), an intermittent but debilitating fatigue occurring after haemodialysis (HD) treatment, is still unclear. In other inflammatory diseases, increasing evidence points toward the involvement of the immune system in the onset of fatigue symptoms. Altered serum levels of inflammatory cytokines have also been shown in HD patients. Therefore, we investigated whether pre- and postdialysis serum levels of pro- and anti-inflammatory cytokines (i.e. IL-1 beta, IL-6, TNF-alpha and IL-10) or their intradialytic changes (if any) were related to PDF or the time HD patients reported needing to recover from HD treatment (TIRD). Methods: Serum levels of IL-1 beta, IL-6, TNF-alpha and IL-10 were measured immediately before and after HD in 45 patients using commercially available kits on an ELLA (TM) automated immunoassay system. The presence and severity of PDF as well as TIRD duration were assessed by self-report measures. Key results: Seventy-four percent of patients reported PDF, with a median PDF severity index of 3.30 [IQR: 3.00-4.30] on a scale from 1 to 5. Median TIRD was 120 min [IQR: 60-480]. PDF severity correlated strongly with TIRD, r(s) = 0.85, p < 0.001. Only predialysis levels of IL-10 significantly and positively correlated with PDF severity (r(s) = 0.43, p = 0.003). Conclusion: Findings of the present study do not support the involvement of the immune system in the onset of PDF or the time patients needed to recover from HD treatment. A positive, but counterintuitive relationship was found between predialysis levels of anti-inflammatory IL-10 and PDF severity, which warrants further research.

Vitiligo is a depigmentary disease in which epidermal melanocytes are lost. It is considered to be an autoimmune disease. Lenalidomide, an immunomodulatory drug is being employed in the treatment of various autoimmune and inflammatory disorders. In the present manuscript, the effect of lenalidomide on T cells and major cytokines in the cultured peripheral blood mononuclear cells (PBMCs) derived from vitiligo patients was checked. Eight patients with a clinical diagnosis of active vitiligo volunteered for the study. Blood was collected from them and PBMCs were isolated, cultured, and treated with lenalidomide. After 72 hours, PBMCs were harvested and checked for CD8(+) and CD4(+) T cells by flow cytometry. Further supernatant was collected and the levels of cytokines namely tumor necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma), interleukin-10 (IL-10), and interleukin-4 (IL-4) were checked using ELISA kits. Lenalidomide nonsignificantly decreased the level of CD8(+) T cells but increased CD4(+) T cells leading to increased CD4(+)/CD8(+) T cell ratio. It declined the level of pro-inflammatory cytokines, that is, TNF-alpha and IFN-gamma whereas elevated anti-inflammatory cytokines, that is, IL-10 and IL-4, thus ultimately decreasing the ratio of pro-inflammatory to anti-inflammatory cytokines. Lenalidomide suppressed the proliferation of T lymphocytes and modulated the cytokines secretion toward an anti-inflammatory profile.